Adverse events from systemic therapies for psoriasis.

News items, essays, documents and studies of relevant interest.

Adverse events from systemic therapies for psoriasis.

Postby Nick Balgowan » Sun Nov 12, 2006 11:25 pm

1: J Dermatolog Treat. 2006 Sep;17(5):288-293. Links

Adverse events from systemic therapies for psoriasis are common in clinical Practice

Pearce DJ, Higgins KB, Stealey KH, Balkrishnan R, Crane MM, Camacho F, Fleischer Jr AB, Feldman SR.

Departments of Dermatology.

Background: Patients with moderate-to-severe psoriasis frequently require systemic treatment and these medications may be associated with adverse effects. Little is known about the frequency of these events when systemic agents are used in true clinical practice. Objective: To determine the frequency of adverse events associated with various systemic psoriasis therapies. Methods: A retrospective chart review of 753 patients treated in an academic dermatology practice was performed to identify the frequency of adverse events. Poisson regression was used to estimate the odds of significant events for each systemic therapy; UVB-treated patients served as a control population. Results: Methotrexate seemed to be the most prescribed medication. Adverse events were noted with all forms of systemic psoriasis therapy. The highest event rate was seen with oral retinoids, though most of these were considered minor (64%). Cyclosporine had the highest significant adverse event rate (0.9 events/patient). For 'significant' adverse events, oral agents had an adjusted odds ratio>6 compared to standard UVB therapy. The highest risk was for cyclosporine (OR = 20.3); however, the estimate was imprecise (95% confidence interval [4.3, 96.6]). Conclusions: Traditional psoriasis therapies are associated with significant adverse events in some patients despite toxicity-sparing approaches such as combination therapy. Clinicians need to be aware of screening for adverse events in order to best ensure the safety of their patients and to maximize the efficacy of a given agent. There is still a need for the development of safe and effective treatments for patients with moderate-to-severe psoriasis.

PMID: 17092859 [PubMed - as supplied by publisher]
Nick Balgowan.
----------------------------------------
http://www.tcgindustrial.com.au
http://www.dermaray.com
http://www.beatpsoriasis.com
----------------------------------------
User avatar
Nick Balgowan
Site Admin
 
Posts: 267
Joined: Mon Jan 09, 2006 12:29 pm
Location: Australia

Return to Media articles

Who is online

Users browsing this forum: Google [Bot] and 1 guest

cron